253 related articles for article (PubMed ID: 33216881)
1. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
Crea F
Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
[No Abstract] [Full Text] [Related]
2. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
Berendse J; Newenhouse L
S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
[No Abstract] [Full Text] [Related]
4. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Caruso I; Cignarelli A; Laviola L; Giorgino F
Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
[No Abstract] [Full Text] [Related]
5. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
[No Abstract] [Full Text] [Related]
6. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
[No Abstract] [Full Text] [Related]
7. Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
Chilton RJ
Diabetes Obes Metab; 2021 May; 23(5):1215-1218. PubMed ID: 33464709
[No Abstract] [Full Text] [Related]
8. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
9. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
[TBL] [Abstract][Full Text] [Related]
10. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
Vaduganathan M; Januzzi JL
Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
[TBL] [Abstract][Full Text] [Related]
11. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors.
Karagkounis D
Drug Ther Bull; 2023 Jul; 61(7):103-107. PubMed ID: 37380347
[TBL] [Abstract][Full Text] [Related]
12. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.
Khan MS; Fonarow GC; Greene SJ
Eur J Heart Fail; 2021 Jun; 23(6):1023-1025. PubMed ID: 33779013
[No Abstract] [Full Text] [Related]
14. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
[No Abstract] [Full Text] [Related]
15. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
Petrie MC; Lee MMY; Docherty KF
Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
[No Abstract] [Full Text] [Related]
16. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
[No Abstract] [Full Text] [Related]
17. Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.
Cure E; Cumhur Cure M
Am J Cardiol; 2020 May; 125(10):1602. PubMed ID: 32241553
[No Abstract] [Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibitors in heart failure.
Rosano GMC; Vitale C; Savarese G
Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
[No Abstract] [Full Text] [Related]
19. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
20. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure.
Attachaipanich T; Chattipakorn SC; Chattipakorn N
J Cell Physiol; 2022 May; 237(5):2404-2419. PubMed ID: 35324001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
